Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study
Katharina Mohr,Philipp Mildenberger,Thomas Neusius,Konstantinos C Christodoulou,Ioannis T Farmakis,Klaus Kaier,Stefano Barco,Frederikus A Klok,Lukas Hobohm,Karsten Keller,Dorothea Becker,Christina Abele,Leonhard Bruch,Ralf Ewert,Irene Schmidtmann,Philipp S Wild,Stephan Rosenkranz,Stavros V Konstantinides,Harald Binder,Luca Valerio,Stefano Barco,Dorothea Becker,Brunhilde Fischer,Lukas Hobohm,Anja Käberich,Karsten Keller,Frederikus A Klok,Stavros V Konstantinides,Nadine Martin,Anna C Mavromanoli,Silke Otto,Kai-Helge Schmidt,Luca Valerio,Philipp S Wild,Leonhard Bruch,Stefanie Geistert,Katrin Schüler,Ralf Ewert,Claudia Pohl,Jeannette Pieper,Martin Faehling,Birgit Blaich,Annika Landmesser,Stephan Rosenkranz,Felix Gerhardt,Jasmin Rudolph,Sibel Gün,Hossein-Ardeschir Ghofrani,Ute George,Ekkehard Grünig,Benjamin Egenlauf,Amina Salkić,Eva-Maria Heier,Michael Halank,Kristin Tausche,Tina Rink,Diana Jäkel,Matthias Held,Barbara Schröder,Marius M Hoeper,Julia Freise,Susanne Tayler,Hanno H Leuchte,Annika Horn,F Joachim Meyer,Dagmar Emge-Rossa,Karine Thabaret,Claus Neurohr,Juergen Barton,Christian Opitz,Ines Bressem,Hans-Jürgen Seyfarth,Patricia Berger,Angela Hennig,Rolf Wachter,Kristian Hellenkamp,Carmen Sentler,Martina Schulte,Heinrike Wilkens,Franziska Trudzinski,Ines Holtz,Eckhard Mayer,David Fistera,Aleksandar Grgic,
DOI: https://doi.org/10.1093/ehjqcco/qcae050
2024-07-01
European Heart Journal - Quality of Care and Clinical Outcomes
Abstract:Abstract Aims Patients surviving acute pulmonary embolism (PE) necessitate long-term treatment and follow-up. We estimated, the chronic economic impact of PE on the German healthcare system. Methods and results We calculated the direct cost of illness during the first year after discharge for the index PE, analysing data from a multicentre prospective cohort study in Germany. Main and accompanying readmission diagnoses were used to calculate DRG-based hospital reimbursements; anticoagulation costs were estimated from the exact treatment duration and each drug's unique national identifier; and outpatient post-PE care costs from guidelines-recommended algorithms and national reimbursement catalogues. Of 1017 patients enrolled at 17 centres, 958 (94%) completed ≥3-month follow-up; of those, 24% were rehospitalized (0.34 [95% CI 0.30–0.39] readmissions per PE survivor). Age, coronary artery, pulmonary and kidney disease, diabetes, and (in the sensitivity analysis of 837 patients with complete 12-month follow-up) cancer, but not recurrent PE, were independent cost predictors by hurdle gamma regression accounting for zero readmissions. The estimated rehospitalization cost was €1138 (95% CI 896–1420) per patient. Anticoagulation duration was 329 (IQR 142–365) days, with estimated average per-patient costs of €1050 (median 972; IQR 458–1197); costs of scheduled ambulatory follow-up visits amounted to €181. Total estimated direct per-patient costs during the first year after PE ranged from €2369 (primary analysis) to €2542 (sensitivity analysis). Conclusion By estimating per-patient costs and identifying cost drivers of post-PE care, our study may inform decisions concerning implementation and reimbursement of follow-up programmes aiming at improved cardiovascular prevention.
cardiac & cardiovascular systems